Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25243640 | 1.00 | TAS1R3 (0.40) | TAS1R3TAS1R1CTSLCTSSCTSK | |
| SCHEMBL25240278 | 1.00 | TAS1R3 (0.40) | TAS1R3TAS1R1CTSLCTSSCTSK | |
| SCHEMBL25286945 | 1.00 | TAS1R3 (0.40) | TAS1R3TAS1R1CTSLCTSSCTSK | |
| SCHEMBL25284002 | 0.87 | TAS1R3 (0.56) | TAS1R3TAS1R1CTSLCTSSCTSK | |
| SCHEMBL25243875 | 0.87 | TAS1R3 (0.56) | TAS1R3TAS1R1CTSLCTSSCTSK | |
| SCHEMBL25286876 | 0.87 | TAS1R3 (0.56) | TAS1R3TAS1R1CTSLCTSSCTSK | |
| SCHEMBL25237451 | 0.86 | TAS1R3 (0.42) | TAS1R3TAS1R1CTSLCTSS | |
| SCHEMBL25244556 | 0.86 | TAS1R3 (0.42) | TAS1R3TAS1R1CTSLCTSS | |
| SCHEMBL25250566 | 0.86 | TAS1R3 (0.42) | TAS1R3TAS1R1CTSLCTSS | |
| SCHEMBL29414261 | 0.86 | TAS1R3 (0.42) | TAS1R3TAS1R1CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4204393-A1 | AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022043374-A1 | AMINOCARBAMOYL COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-03-03 | — | — | WO | disclosed |